Neuroradiology: Technical NoteQuantitative Proton-Decoupled 31P MRS of the Schizophrenic Brain In VivoBlüml, Stefan; Tan, Jeannie; Harris, Kent; Adatia, Navin; Karme, Alan; Sproull, Terrence; Ross, Brian Author Information From the Clinical Magnetic Resonance Spectroscopy Unit, Huntington Medical Research Institutes (S. Blüml, J. Tan, K. Harris, and B. Ross), and Della Martin Center for Behavioral Science, Huntington Memorial Hospital, Pasadena (N. Adatia, A. Karme, and T. Sproull), and Rudi-Schulte Research Institutes, Santa Barbara (S. Blüml and J. Tan), CA, U.S.A. A preliminary report of this work was presented at the 6th ISMRM 1998, Sydney, Australia. Address correspondence and reprint requests to Dr. B. Ross at Huntington Medical Research Institutes, 660 S. Fair Oaks Ave., Pasadena, CA 91105, U.S.A. Journal of Computer Assisted Tomography: March 1999 - Volume 23 - Issue 2 - p 272-275 Buy Abstract Quantitative proton MR spectroscopy (MRS) and proton-decoupled phosphorus MRS were applied in the parietal cortex of 13 schizophrenic subjects (11 drug-treated and 2 neuroleptic-naive) and 15 normal control subjects. Significantly increased concentrations of glycerophosphorylcholine (1.18 ± 0.16 vs. 0.93 ± 0.14 mmol/kg brain; p < 0.001), glycerophosphoethanolomine (0.70 ± 0.19 vs. 0.59 ± 0.07 mmol/kg; p < 0.04), and phosphocreatine (3.73 ± 0.39 vs. 3.41 ± 0.13 mmol/kg; p < 0.007), but no differences in N-acetylaspartate, total creatine, or myo-inositol, were determined in treated schizophrenic subjects. Identical abnormalities were found in two neuroleptic-naive patients. These results provide new evidence of disordered cerebral membrane and high energy phosphate metabolism in schizophrenia. © 1999 Lippincott Williams & Wilkins, Inc.